COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

[HTML][HTML] COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: a scoping review

JM Jones, AJ Faruqi, JK Sullivan… - Pathogens and …, 2021 - ncbi.nlm.nih.gov
Background: The role of humoral immunity has been well established in reducing infection
risk and facilitating viral clearance in patients with COVID-19. However, the relationship …

Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study

P Deepak, W Kim, MA Paley, M Yang… - Annals of internal …, 2021 - acpjournals.org
Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …

COVID-19 vaccine effectiveness against omicron (B. 1.1. 529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective …

M Risk, SS Hayek, E Schiopu, L Yuan… - The Lancet …, 2022 - thelancet.com
Background There is a scarcity of research regarding the effectiveness of the mRNA-1273
(Moderna) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in patients taking …

Absence of humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series

CM Connolly, BJ Boyarsky, JA Ruddy… - Annals of internal …, 2021 - acpjournals.org
Background: Patients with rheumatic and musculoskeletal diseases (RMDs) are at
increased risk for SARS-CoV-2 infection because of both the immunomodulatory effects of …

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273

NJM Verstegen, RR Hagen, J van den Dijssel… - Elife, 2022 - elifesciences.org
Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis

R Cordtz, S Kristensen, R Westermann, K Duch… - …, 2023 - academic.oup.com
Objectives The objectives of this study were to investigate the incidence of COVID-19
hospitalization in unvaccinated and vaccinated patients with RA compared with matched …

COVID-19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune-mediated inflammatory diseases compared to controls

L Eder, R Croxford, AM Drucker, A Mendel… - The Journal of …, 2022 - jrheum.org
Objective To investigate coronavirus disease 2019 (COVID-19) hospitalization risk in
patients with immune-mediated inflammatory diseases (IMIDs) compared with matched non …

Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response

F Filippini, M Giacomelli, C Bazzani, M Fredi… - BMC medicine, 2023 - Springer
Background The impact of immunosuppressive therapies on the efficacy of vaccines to
SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated …

[HTML][HTML] High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients

M Fabris, G De Marchi, R Domenis, F Caponnetto… - Journal of …, 2022 - Elsevier
Objective To evaluate B-cell-and T-cell-mediated immune response to SARS-CoV-2 mRNA
vaccination in patients with complex or rare systemic autoimmune diseases previously been …